The recognition that some 10% to 15% of the hypertensive population may have aldosterone excess has increased the frequency of measurement of the aldosterone-to-renin ratio (ARR) and the use of aldosterone antagonists. Whether this ratio will predict the blood pressure (BP) response to spironolactone is not clear.
U
ntil recently, primary hyperaldosteronism was thought to be an uncommon condition (Ͻ2% in the hypertensive population) characterized by hypokalemic alkalosis and suppressed plasma renin activity in most cases caused by excessive adenomatous aldosterone production. However a number of recent studies have suggested that based on a raised ambulant aldosterone-torenin ratio (ARR), a marker of inappropriate aldosterone activity, the prevalence of primary hyperaldosteronism in the hypertensive population may be as high as 10% to 15%. 1 Functional hyperaldosteronism in the absence of an adrenal adenoma may contribute to hypertension, and it has been suggested that these patients show a marked fall in blood pressure (BP), particularly systolic, with aldosterone antagonism using spironolactone. 2 In addition, a subset of patients with resistant low-renin hypertension may show marked responsiveness to spironolactone. 3 However these studies 2, 3 did not specifically relate drug response to baseline aldosterone and renin.
Interest in the contribution of aldosterone to hypertension has been rekindled by its possible role in the pathogenesis of vascular damage. There is evidence that aldosterone has a BP-independent effect on left ventricular structure, increasing collagen deposition and fibrosis, and on the development of diastolic and systolic dysfunction. 4 Recently a significant correlation between the ARR, a marker of aldosterone activity, and arterial stiffness, a major determinant of cardiovascular risk in the hypertensive population, has been established. 5 Patients with hyperaldosteronism have greater cardiovascular risk and end-organ damage than matched subjects with essential hypertension 4 and are more likely to have resistant hypertension than other hypertensive subjects. 2, 4 Although some early studies 6, 7 have suggested that spironolactone is more effective in patients with low-renin hypertension, the hallmark of primary hyperaldosteronism, other studies did not confirm this observation. 8, 9 A recent study in treated patients with resistant hypertension using lower doses of spironolactone (Յ50 mg/day) did not find any relationship among renin, aldosterone, or the ARR and the response in patients with resistant hypertension. 10 Introduction of the ambulatory ARR overcame some of the problems associated with the influences of the time of day, dietary salt intake, and posture on both renin and aldosterone and is now an established technique for assessing relative aldosterone activity. 2 We therefore determined the relationship between the ARR and the response to spironolactone in two groups of patients: 1) those with newly diagnosed, never-treated hypertension, and 2) those with established long-standing hypertension resistant to standard antihypertensive therapy.
Patients and Methods
A total of 69 patients of white ethnicity (45 men and 24 women, mean (ϮSEM) age 57 Ϯ 2 years) with essential hypertension (clinic BP Ͼ140/90 mm Hg on three occasions and ambulatory daytime BP Ͼ135/85 mm Hg were studied. One group (n ϭ 30, 18 women and 12 men) comprised of patients who 1) had never received antihypertensive treatment, 2) were not on any prescribed diet or agents that interfered with BP control, salt, or potassium balance, and 3) had no concomitant medication or illnesses (fasting glucose 5.5 Ϯ 0.6 mmol/L, creatinine 84 Ϯ 12 mol/L and potassium 4.2 Ϯ 0.2 mmol/L). Patients were screened to exclude possible secondary causes of hypertension, including urinary catecholamines and magnetic resonance angiography of renal arteries when appropriate. These patients were randomized to receive either spironolactone 50 mg/day or bendroflumethiazide 2.5 mg/day in a cross-over design for 4 weeks with an intervening 4-week washout period. Blood pressure was measured in the morning in each patient, after a supine rest of 15 min, by an independent observer using an oscillometric device (Omron HEM 705 CP) before and after 4 weeks of therapy, in triplicate, and was averaged. The study was approved by the Institutional Review Board.
The second group comprised of 39 treated patients (27 men and 12 women) who were drawn from a Hypertension Clinic and had an inadequate BP response to standard antihypertensive treatment and BP Ͼ140/90 mm Hg on two consecutive clinic visits, despite administration of three or more antihypertensive agents in therapeutic doses. The mean duration of hypertension was 4.0 Ϯ 0.4 years, and in approximately 30% of cases these patients had received a fourth antihypertensive drug. Four had type 2 diabetes and three had previous myocardial infarction. The mean creatinine was 94 Ϯ 3 mol/L and potassium 3.7 Ϯ 0.1 mmol/L. Concomitant medication included ␤-blockers (n ϭ 32), angiotensin-converting enzyme (ACE) inhibitors (n ϭ 29), diuretics (n ϭ 27), calcium channel blockers (n ϭ 20), angiotensin receptor antagonists (ARB) (n ϭ 9), ␣-blockers (n ϭ 4), and methyldopa (n ϭ 1). Eleven were taking aspirin and eight were taking statins. These patients were administered spironolactone 50 mg/day and reviewed at the clinic 3 to 4 months later. A single measurement of BP was made in the morning in the sitting position using a mercury sphygmomanometer by an independent observer who was unaware of any biochemical data.
Aldosterone (pmol/mL) and plasma renin activity (ng/ mL/h) were measured by radioimmunoassay (Adaltis Italia Inc, Bologna, Italy) from samples drawn in the morning, with the patients ambulant and having fasted overnight and rested in seated position for 10 min.
Statistical analysis was performed with JMP Version 3.01 (SAS for Windows; SAS Institute, Cary, NC) using nonparametric methods, as the data were not normally distributed. The ARR was transformed to log ARR. Relationships between different parameters were analyzed using Spearman correlations, and the change in biochemical and hemodynamic parameters was analyzed with the Wilcoxon signed rank sums test. The relationship between ARR and reductions in BP was adjusted for age using a stepwise regression model, taking changes in BP as the independent variable and both age and log ARR as dependent variables. All results are expressed as mean Ϯ SEM. Values of P Ͻ .05 were considered to be significant.
Results
The mean values for plasma aldosterone, plasma renin activity and the ARR were 680 Ϯ 62 pmol/mL, 1.48 Ϯ 0.2 ng/mL/h and 891 Ϯ 142 respectively in the untreated and 634 Ϯ 37,1.4 Ϯ 0.7 and 1972 Ϯ 231 in the treated patients. The number of patients with low renin (Յ0.5 ng/mL/h) was 10 in the untreated group and 24 in the treated group. Ten patients in the untreated group had a raised ARR (Ͼ800), whereas in the treated group 29 patients had an elevated ARR.
In the patients with newly diagnosed hypertension, spironolactone 50 mg reduced systolic BP by 18 Ϯ 3 mm Hg and diastolic BP by 11 Ϯ 1 mm Hg. There were no adverse reactions to therapy. There was a highly significant correlation between log ARR and the fall in systolic BP (r ϭ 0.69, P Ͻ .001) and diastolic BP (r ϭ 0.45, P Ͻ .05) (Fig. 1) . For plasma renin activity alone the correlations were r ϭ Ϫ0.58, P Ͻ .01 and r ϭ Ϫ0.36, P Ͻ .05 respectively. There was a significant correlation between age and the fall in systolic BP (r ϭ 0.39, P Ͻ .05) but not diastolic BP (r ϭ 0.05, NS). However the correlation between log ARR and fall in systolic BP remained significant after correction for age (r ϭ 0.63, P Ͻ .001). There was no relationship between the degree of fall in BP and the plasma aldosterone or potassium levels. Four patients with a plasma aldosterone level Ͻ400 pmol/mL, had a reduction in systolic BP of Ͼ20 mm Hg .
For patients (n ϭ 8) with ARR Ͼ800 and aldosterone Ͼ 400 pmol/mL the fall in BP exceeded that of the other 22 (27 Ϯ /16 Ϯ 1 v 13 Ϯ 3/10 Ϯ 2 mm Hg, P Ͻ .05), and for six of these patients the fall in systolic BP was Ն20 mm Hg, which is regarded as a positive response to spironolactone.
1 Among patients with ARR Ͻ400 (n ϭ 8), only one had a fall of Ն20 mm Hg. Among patients (n ϭ 10) with low renin activity (Յ0.5 ng/mL/h), the systolic BP fall was Ն20 mm Hg in nine. No such relationships were seen between ARR or renin subgroups and BP reduction after bendroflumethiazide.
For patients previously on treatment the reduction in BP after spironolactone 50 mg for mean duration of 3.7 Ϯ 0.4 months was 28 Ϯ 3/13 Ϯ 2 mm Hg from 167 Ϯ 3/95 Ϯ 2 to 139 Ϯ 3/82 Ϯ 2 mm Hg (P Ͻ .01). There were no significant correlations between the reduction in either systolic or diastolic BP and log ARR or renin activity. A high ARR (Ͼ800) did not predict responsiveness. Patients with pretreatment potassium levels Ͻ4.0 mmol/L (n ϭ 26) had a greater reduction in BP (34 Ϯ 3/16 Ϯ 2 v 20 Ϯ 6 / 8 Ϯ 3 mm Hg, P Ͻ .05) than those with levels Ն4.0 mmol/L (n ϭ 13). Treatment was associated with a significant increase (P Ͻ .01) in plasma potassium (3.7 Ϯ 0.07 to 4.2 Ϯ 0.09 mmol/L) and creatinine (93 Ϯ 3 to 101 Ϯ 4 mol/L) and a nonsignificant fall in sodium (139 Ϯ 0.4 to 138 Ϯ 0.4 mmol/L). Two patients, both taking ACE inhibitors, developed hyperkalemia (5.2 and 5.5 mmol/L), and five (18.5% of men) developed gynecomastia.
Discussion
These data suggest that the antihypertensive effect of the aldosterone antagonist, spironolactone, is related to activity of the renin-angiotensin-aldosterone system. In untreated patients, there was a significant positive correlation between the degree of fall in BP and the ARR, a marker of aldosterone activity. However this relationship was not found in patients taking multiple antihypertensive agents. This apparent discrepancy may in part be explained by concomitant use of medications. Antihypertensive agents may significantly alter both plasma renin activity and, to a lesser extent, aldosterone concentrations. Mulatero et al 11 screened 230 treated patients for primary aldosteronism but excluded patients with resistant hypertension. After a 1-month washout from previous therapies, the subjects were allocated to treatment with single antihypertensive drugs. It was noted that the ARR was changed significantly more by the ␤-blocker atenolol (increased by 62% Ϯ 82%) than by any other agent. Both ACE inhibition with lisinopril and angiotensin receptor blockade with irbesartan decreased the ratio by 30% Ϯ 22% and 43% Ϯ 27% respectively, whereas ␣-blockade with doxazosin decreased the ratio by 5% Ϯ 6% and calcium channel blockade with amlodipine decreased the ratio by 17% Ϯ 32%. The use of a ratio may, however, mask the divergent effects on individual components. For example, renin was reduced by atenolol but was raised by lisinopril, amlodipine, and irbesartan, whereas aldosterone was reduced by atenolol, lisinopril, amlodipine, and irbesartan. Given the considerable variation in these drug effects on both renin and aldosterone with no way of predicting the possibly synergistic or antagonistic effect of multiple agents used simultaneously, withdrawal of therapy or possibly the use of ␣-blockade as monotherapy seems the practical solution if ARR is to be of use in detecting primary aldosteronism. In addition aldosterone and renin do not always move in a parallel interdependent fashion, and potassium is a major determinant of aldosterone secretion. The fact that it was relatively low (3.7 mmol/L), possibly because of longstanding use of diuretics in resistant treated hypertensive patients compared with untreated (4.2 mmol/L) patients may also be a factor influencing both ARR and BP response to a potassium-sparing diuretic that increased potassium by 0.5 mmol/L. Indeed the pretreatment potassium levels predicted the extent of BP fall with a 80% greater reduction in mean arterial pressure in subjects with levels Ͻ4 mmol/L.
A number of early studies 8, 9 failed to show a relationship between renin status and the response to spironolactone 100 to 400 mg/day. In contrast, however, Brooks et al 7 showed a greater response in patients with low as opposed to normal renin values, and Karlberg et al 6 in a comparison between spironolactone 200 mg/day and propranolol 320 mg/day found that patients responded better to the latter if renin levels were high, whereas patients with low renin values responded better to spironolactone. 6, 7 In a dose-response study patients given 50 to 200 mg of spironolactone, it was shown that those with the greater response to spironolactone were characterized by older age and low plasma renin activity. 12 Our data confirms this finding, which is not unexpected, inasmuch as older hypertensive patients tend to have low renin values. However we found that the relationship to ARR persisted when adjusted for age. More recently, Lim et al, in an uncontrolled observational study of patients with poorly controlled hypertension and a raised ARR, showed that the addition of spironolactone reduced the need for antihypertensive drugs by Ϫ0.5 as well as reducing the mean BP by 15/8 mm Hg. 2 Nishizaka et al 10 added low-dose spironolactone (25 to 50 mg daily) in patients with resistant hypertension to a regimen that included an ARB or an ACE inhibitor. Most of the 76 patients, 41 of whom were African American, had low renin levels and might therefore have been expected to show BP responses to spironolactone treatment. Of the 76 patients, 34 were considered to have primary aldosteronism, but this was diagnosed while patients were receiving medications that would have affected aldosterone and renin levels. Not surprisingly, therefore, the BP reduction with spironolactone (25 Ϯ 20 / 12 Ϯ 12 mm Hg at 6 months) was similar in subjects diagnosed with or without primary aldosteronism, and was additive to the use of a diuretic and ACE inhibitor or ARB. There was no relationship between BP response and the ARR, but the concomitant use of other medications could have confounded this analysis.
More recently this issue has been explored with the newer specific aldosterone antagonist, eplerenone. Flack et al 13 compared the efficacy and tolerability of eplerenone and losartan in hypertensive patients of white and African American ethnicities. As expected eplerenone produced a significantly greater reduction in systolic and diastolic BP than losartan in moderately low renin patients (many African American), and there was a trend for the extent of BP reduction with eplerenone to be related to renin tertiles. However, eplerenone was also more effective than losartan in reducing systolic BP in patients with either low or high aldosterone levels. The relationship of BP reduction with the aldosterone renin ratio was not reported. In a multicenter study of 341 patients, in which eplerenone or placebo was added to therapy in patients whose hypertension was not controlled by an ACE inhibitor or ARB monotherapy, baseline value of active plasma renin, plasma aldosterone, or the ARR did not predict the antihypertensive response. 14 We believe that our results are clinically relevant although we must be cautious because the numbers are relatively small. For untreated patients, although the study was short-term it was randomized and controlled. We believe that it helps to identify patients who are likely to have a good response to spironolactone (Ͼ20 mm Hg fall in systolic BP), as seen in six of eight patients with ARR Ͼ800 and elevated aldosterone (Ͼ400 pmol/mL), equivalent to a ratio of almost 30 and plasma aldosterone Ͼ15 ng/dL in conventional units, and those unlikely to respond (ie, those with ARR Ͻ400, of whom only one of eight responded). Indeed although the relationship, when considered as a continuous variable to BP response, was of lesser significance than for ARR, plasma renin activity is perhaps more predictive in that nine of 10 subjects with low levels (Յ0.5 ng/mL/h) were good responders. This may in part be caused by the lack of a relationship with aldosterone, as some subjects with low levels appeared to be good responders. The question as to whether some of the patients with high ARR had primary aldosteronism cannot be answered with certainty, as formal suppression testing was not carried out.
The study of patients with resistant hypertension, although uncontrolled, was single blind. Such patients were taking a variety of medicines, and one third had previously tried on a fourth agent with an inadequate BP response. The relatively late review at 3 to 4 months reflects normal clinic practice. It is in this group of patients that the risk of hyperkalemia is greatest.
Taken in conjunction with our data, studies suggest that for the lower doses of spironolactone currently used, and possibly also for eplerenone, low renin status or a raised aldosterone-to-renin ratio may be predictive of the antihypertensive response to aldosterone antagonism as monotherapy. However for patients with chronic therapy and resistant hypertension, presumably because of the interaction between other antihypertensive agents with both aldosterone and renin, the ARR is not predictive of the extent of BP response to aldosterone antagonism. Nonetheless such patients, particularly those with low potassium values, often respond well to spironolactone; however the decision to use this agent would need to take into account the potential for adverse effects such as gynecomastia, hyperkalemia and azotemia.
